These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12053404)

  • 21. [New developments also in general medicine. GSK relies on research as well as transparent collaboration with physicians (interview by Dirk Einecke, Wolfgang van den Bergh, Peter Overbeck and Cornelius Heyer)].
    Marshall CG; Strohmeyer T
    MMW Fortschr Med; 2011 May; 153(21):10-1. PubMed ID: 21739676
    [No Abstract]   [Full Text] [Related]  

  • 22. India tries to improve national system for handling clinical trials.
    Sharma DC
    Lancet; 2001 May; 357(9269):1682. PubMed ID: 11425387
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 24. [Legal liability in clinical trials from the legal-pharmaceutical viewpoint].
    Amon F
    Z Arztl Fortbild (Jena); 1995 Nov; 89(6):638-41. PubMed ID: 8588437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

  • 26. [Off-label use of drugs--the legal framework].
    Koyuncu A
    Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
    [No Abstract]   [Full Text] [Related]  

  • 27. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Databases as a source for monitoring systems of drug safety].
    Pigeot I; Ahrens W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jun; 47(6):513-7. PubMed ID: 15221098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obstacles encountered in designing antiepileptic drug trials.
    French JA
    Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
    [No Abstract]   [Full Text] [Related]  

  • 31. Future developments of clinical research in pediatrics: the role of the Journal Klinische Pädiatrie.
    Körholz D; Gortner L; Göbel U
    Klin Padiatr; 2013 Jul; 225(4):191-2. PubMed ID: 23904155
    [No Abstract]   [Full Text] [Related]  

  • 32. [Patient education responsibility, specialty and administration information from the viewpoint of the pharmaceutical industry].
    Granitza A
    Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):649-53. PubMed ID: 9527462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Network for investigation of medicinal products in children].
    Kassaï B; Treluyer JM; Jacqz-Aigrain E; Pons G
    Arch Pediatr; 2006 Jun; 13(6):631-4. PubMed ID: 16697606
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 35. [Off-label use in dermatological practice. The conflict between professional duty and legal requirements].
    Brunne V; Mertins G; Reimann G; Brockmeyer NH
    Hautarzt; 2004 Aug; 55(8):727-34. PubMed ID: 15241515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges and opportunities in bringing new medications to market for pediatric patients.
    Upadhyaya HP; Gault L; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
    [No Abstract]   [Full Text] [Related]  

  • 37. Patients, physicians, and clinical trials: the other side of the coins.
    Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
    J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
    [No Abstract]   [Full Text] [Related]  

  • 38. Indian Supreme Court halts approval of new clinical trials until regulatory framework is set up.
    Bagcchi S
    BMJ; 2013 Oct; 347():f5996. PubMed ID: 24097130
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of the pharmacist in investigational AED trials.
    Graves NM
    Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
    [No Abstract]   [Full Text] [Related]  

  • 40. [Assessment of SUSARs. Clinical evaluation of single cases in terms of regulatory requirements].
    Wroblewski H; Schmickler M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):459-63. PubMed ID: 15830258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.